At the height of the COVID-19 pandemic, biotech companies swiftly responded with innovative solutions in record time. Despite ongoing variants, the demand for treatment is expected to decline at a 20.73% compound annual growth rate through 2028, according to a research firm, Statista. It’s an interesting time for newcomer Invivyd (NASDAQ:IVVD) to bring its first clinical treatment targeting COVID-19 prevention in immunocompromised patients to market. It may be a case of too little, too late for the company, making the stock a highly speculative play for investors.
New Treatment Available for At-Risk Group
Invivyd is a clinical-stage biopharmaceutical company engaged in developing and commercializing antibody-based solutions targeting infectious diseases like COVID-19. The company’s primary pivotal offering is PEMGARDA, a preventive solution for COVID-19 for certain adults and adolescents with significant immune…
